我們已在上線！進一步了解

Incyte

INCY

市值 US$229億

113.07 USD

-0.20

0.18%

收盤時已更新 10月16日下午4:00 EDT

盤前交易

盤後交易

112.30

-0.77

0.68%

1天

-0.18%

5天

-0.86%

1個月

-9.36%

3個月

-3.07%

6個月

18.62%

今年迄今

11.49%

1年

29.5%

5年

75.09%

10年

30.42%

關於： Incyte focuses on the discovery and development of small-molecule drugs. The firm's leading drug, Jakafi, treats two types of rare blood cancer and graft versus host disease and is partnered with Novartis. Incyte's other marketed drugs include rheumatoid arthritis treatment Olumiant (licensed to Lilly), and oncology drugs Iclusig (chronic myeloid leukemia), Pemazyre (cholangiocarcinoma), Tabrecta (lung cancer), and Monjuvi (diffuse large B-cell lymphoma). The firm's first dermatology product, Opzelura, was approved in 2021 for atopic dermatitis and 2022 for vitiligo. Incyte's pipeline includes an array of oncology and dermatology programs.

員工： 2,844

醫療保健生物科技

新聞

正面

中性

負面

市場情緒 3個月

正面 46.7%

中性 53.3%

負面 0%

Incyte Honors the 2026 MPN Heroes®, Celebrating Champions of the Myeloproliferative Neoplasm (MPN) Community

WILMINGTON, Del.--(BUSINESS WIRE)--Incyte today announced eight winners of the 2026 MPN Heroes® annual recognition program. The program, now in its 14th year, pays tribute to individuals whose contributions to patient care, research and advocacy make a meaningful difference for people affected by myeloproliferative neoplasms (MPNs). The 2026 Heroes join a distinguished group of over 100 past honorees whose remarkable contributions have spurred progress and enriched the lives of people throughou.

Incyte Honors the 2026 MPN Heroes®, Celebrating Champions of the Myeloproliferative Neoplasm (MPN) Community

Incyte to Report Third Quarter Financial Results

WILMINGTON, Del.--(BUSINESS WIRE)--3Q26 Earnings Announcement.

Incyte to Report Third Quarter Financial Results

Knight Therapeutics Announces Regulatory Approval of NIKTIMVO® in Brazil

MONTREAL, Oct. 06, 2026 (GLOBE NEWSWIRE) -- Knight Therapeutics Inc. ("Knight") (TSX: GUD), a pan-American (ex-US) pharmaceutical company, announced today it has received expedited regulatory approval under ANVISA's rare disease pathway for NIKTIMVO® (axatilimab), for the treatment of chronic graft-versus-host disease (cGVHD) after failure of at least two prior lines of systemic therapy in adult and pediatric patients 6 years and older weighing at least 40 kg.1

Knight Therapeutics Announces Regulatory Approval of NIKTIMVO® in Brazil

Zacks Investment Research

INCY or TECH: Which Is the Better Value Stock Right Now?

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Incyte (INCY) and Techne (TECH). But which of these two stocks is more attractive to value investors?

INCY or TECH: Which Is the Better Value Stock Right Now?

Zacks Investment Research

MIRM Secures FDA Nod for an Ultra-Rare Bone Disorder Therapy

Mirum Pharmaceuticals wins FDA approval for Atebrioz in FOP, backed by PROGRESS data showing a reduction in new HO lesion volume.

MIRM Secures FDA Nod for an Ultra-Rare Bone Disorder Therapy

MiniMed appoints Sheila Denton as General Counsel & Corporate Secretary

NORTHRIDGE, Calif., Sept. 28, 2026 /PRNewswire/ -- MiniMed (Nasdaq: MMED), a global leader in diabetes technology, today announced that Sheila Denton has been named General Counsel & Corporate Secretary.

MiniMed appoints Sheila Denton as General Counsel & Corporate Secretary

Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva

FOSTER CITY, Calif. & WILMINGTON, Del.--(BUSINESS WIRE)--Mirum and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva.

Mirum Pharmaceuticals and Incyte Announce U.S. FDA Approval of Atebrioz™ (zilurgisertib) for Adult and Pediatric Patients with Fibrodysplasia Ossificans Progressiva

Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte's Inflammation and Autoimmunity Portfolio

WILMINGTON, Del.--(BUSINESS WIRE)---- $INCY--Incyte Data at the 2026 EADV Congress Underscore the Breadth of Incyte's Inflammation and Autoimmunity Portfolio.

Incyte Data at the European Academy of Dermatology and Venereology (EADV) Congress Underscore the Breadth of Incyte's Inflammation and Autoimmunity Portfolio

Zacks Investment Research

Is First Trust Large Cap Growth AlphaDEX ETF (FTC) a Strong ETF Right Now?

The First Trust Large Cap Growth AlphaDEX ETF (FTC) was launched on 05/08/2007, and is a smart beta exchange traded fund designed to offer broad exposure to the Style Box - Large Cap Growth category of the market.

Is First Trust Large Cap Growth AlphaDEX ETF (FTC) a Strong ETF Right Now?

Incyte Maps Post-JAKAFI Growth With Pipeline Push and $4B Sales Target

Incyte NASDAQ: INCY executives outlined a strategy centered on expanding its non-JAKAFI business, advancing a broader late-stage pipeline and preparing for the loss of exclusivity for JAKAFI after 2029.

Incyte Maps Post-JAKAFI Growth With Pipeline Push and $4B Sales Target

查看新聞排名

價格圖表採用Lightweight Charts™實作